Over half of COVID-19 patients had varied degrees of evidence indicating that on cholangiocytes the SARS-CoV-2 virus may adhere to the angiotensin 2 converting enzyme (ACE2), resulting in cholangiocyte malfunction and a systemic inflammatory response that leads to liver damage, according to new research [8]. This evidence concerns the gene ACE2 and COVID-19.